DEVELOPMENT OF A MODEL TO ASSESS THE COST-EFFECTIVENESS OF THERAPIES FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) FOLLOWING A REFERENCE MODEL FRAMEWORK

被引：0
|
作者：
Aguiar-Ibanez, R. [1 ]
Palencia, R. [2 ]
Kandaswamy, P. [3 ]
Flavin, J. [4 ]
Gauthier, A. [5 ]
Davies, M. J. [6 ]
机构：
[1] Amaris Consulting Uk, London, England
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[3] Boehringer Ingelheim Uk, Bracknell, Berks, England
[4] Boehringer Ingelheim Canada Ltd, Burlingon, ON, Canada
[5] Amaris, London, England
[6] Univ Leicester, Leicester, Leics, England
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1859
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM107
引用
收藏
页码：A562 / A562
页数：1
相关论文
共 50 条
  • [41] Safety and Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus (T2DM) in South Korea
    Kim, Hun-Sung
    Min, Kyungwan
    Kim, Sang Soo
    Kim, Eun Sook
    Chung, Yoon-Sok
    Chung, Choon H.
    Yun, Jae-Seung
    Kim, Won
    Kim, Dong Han
    Yoo, Soon Jib
    DIABETES, 2024, 73
  • [42] DAPAGLIFLOZIN: COST-EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES (T2DM) IN ARGENTINA AND CHILE
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Asteazaran, S.
    Aiello, E.
    Garrido Lecca, S.
    Alvarez, A.
    Roberts, M.
    Cortes Cuadra, P.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [43] COST-EFFECTIVENESS OF THE ROUX-EN-Y GASTRIC BYPASS SURGERY COMPARED WITH MEDICAL MANAGEMENT FOR TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE USA
    Minshall, M. E.
    Swan, T.
    Slusarek, B.
    Ikramuddin, S.
    VALUE IN HEALTH, 2008, 11 (06) : A507 - A507
  • [44] THE COST-EFFECTIVENESS OF GETTING TO GLUCOSE, BLOOD PRESSURE, AND LIPID GOALS IN PATIENTS NEWLY DIAGNOSED WITH TYPE 2 DIABETES MELLITUS (T2DM) AND YOUNGER THAN FIFTY IN SWEDEN
    He, J.
    Neslusan, C.
    Willis, M.
    Worbes-Cerezo, M.
    VALUE IN HEALTH, 2011, 14 (07) : A479 - A479
  • [45] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WITH INADEQUATE CONTROL ON METFORMIN (MET) MONOTHERAPY IN THE UNITED KINGDOM
    Schroeder, M.
    Johansen, P.
    Thompson, G.
    Willis, M.
    Neslusan, C.
    VALUE IN HEALTH, 2014, 17 (07) : A344 - A344
  • [46] COST-EFFECTIVENESS ANALYSIS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) AS AN ADD-ON TO METFORMIN (MET) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED STATES
    Neslusan, C.
    Teschemaker, A.
    Martin, S.
    Willis, M.
    Johansen, P.
    VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [47] The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK
    Thompson, G.
    Schroeder, M.
    Neslusan, C.
    Willis, M.
    Johansen, P.
    Teschemaker, A.
    DIABETOLOGIA, 2014, 57 : S330 - S330
  • [48] Inappropriate metformin prescribing in elderly type 2 diabetes mellitus (T2DM) patients
    Kosmalski, M.
    Drozdowska, A.
    Sliwinska, A.
    Drzewoski, J.
    ADVANCES IN MEDICAL SCIENCES, 2012, 57 (01): : 65 - 70
  • [49] Cause of Hospitalizations in Patients with Type 2 Diabetes Mellitus (T2DM) in the CANVAS Program
    Mahaffey, Kenneth W.
    Ianus, Juliana
    Damaraju, C. V.
    Neal, Bruce
    De Zeeuw, Dick
    Fulcher, Greg
    Pfeifer, Michael
    Matthews, David R.
    DIABETES, 2019, 68
  • [50] Characteristics of Patients with Type 2 Diabetes Mellitus (T2DM) Initiating Therapy with Canagliflozin
    Martin, Silas C.
    Henk, Henry J.
    Chow, Wing
    DIABETES, 2014, 63 : A307 - A307
12345